GW Pharmaceuticals (NASDAQ: GWPH), one of the five stocks I told you to own in 2016, soared at the open after the company announced positive phase III trial results...
Forward to a Friend
Refer a Friend to Wealth Daily
Having trouble viewing this issue? View Online
Advertisement

Live out ALL of your wildest fantasies...

... And still have enough money left over to leave a generous nest egg for your kin.

Take Anne Simpkins in New York City. This little-known technique she discovered was so lucrative that she left her family with $22 million!

Now THAT, my friend, is what I call TRUE FREEDOM. So isn’t it about time you take the first step towards it?

Click here now to learn more.

FDA Approves Marijuana!
By Jeff Siegel | Tuesday, March 15, 2016

Yesterday morning, legal marijuana investors woke up to this...

gwphboom

GW Pharmaceuticals (NASDAQ: GWPH), one of the five stocks I told you to own in 2016, soared at the open after the company announced positive phase III trial results.

GW Pharmaceuticals has developed a cannabis-related drug for children that suffer from severe epilepsy. And with this latest news, the company can now use its data to file for FDA approval. Once approved, this will be the first cannabis-derived medicine to ever be approved by the FDA.

If you took my advice back in December, congratulations on doubling your money. If you didn't, don't worry. Because there's more of this to come.

Advertisement

Trudeau Small

Canadian Prime Minister Justin Trudeau is completely legalizing marijuana in Canada, effectively making drug dealing legal.

Here’s how YOU can get a piece of this action right now!

Just Getting Started

If you're a regular reader of these pages, you know I'm extremely bullish on the legal marijuana space. Quite frankly, it's just the easiest money to be made in the market today.

Prohibition in the U.S. is on its way out.

In Canada, it'll officially be over next year, thanks to the country's new Prime Minister, Justin Trudeau. And in Mexico, the Supreme Court has given the nod to allow Mexican citizens to grow their own marijuana.

As I've mentioned in the past, we are at the dawn of a North American legal marijuana trade that's already worth billions. And this thing is just getting started.

What Merrill Lynch Secretly Likes

While GWPH shareholders are doing backflips now that phase III trials have shown success, this is just one in a portfolio of legal marijuana stocks that are making investors rich.

From growers to retailers to testing companies, the opportunities are endless.

The biggest opportunities are likely to be found in what's called “Life Science Tools.” This is basically equipment that's used to test marijuana for potency and quality. Certainly analysts at Merrill Lynch are bullish.

Just a few months ago, a 45-page equity report from Merrill Lynch was leaked to a reporter in Philadelphia. This report noted that estimates for the equipment market could reach $100 million by 2020. Folks, that's less than four years away.

Advertisement

Secret algorithm predicts 67,350% stock run

It's taken more than 75,000 man-hours to develop...

It runs continuously, evaluating and ranking millions of patents and thousands of public and private companies...

Which is precisely how it predicted mega-profit stock runs of 19,950%, 49,893%, and 67,350%.

If you'd been following this powerful intel, any one of these gains could have been yours...

Now the same secret algorithm has pinpointed its next multi-thousand percent winner.

Get the details here for free.

Of course, for investors, there are no pure play marijuana testing companies. At least none that are publicly traded. However, there is one private company that you can invest in if you're an accredited investor. And quite frankly, this is one of the most lucrative marijuana testing companies in the United States, already generating millions in revenue.

In two weeks, I'll be revealing the name of this company, along with all the specific details on how you can invest in this company without having to buy shares on the public markets. But to get access to this deal, you must be a member of my Green Chip Stocks private investment community.

Green Chip Stocks focuses on renewable energy, organic food, and legal marijuana markets. The latter is where we're making most of our money these days. And not just on private deals.

In fact, three of our legal marijuana stocks are poised to deliver gains in excess of what GWPH delivered on Monday. Two are already up over 90%!

These are three Canadian marijuana plays that have already done deals with the Canadian government to take full advantage of legalization, which is set for approval at the end of the year.

To learn more about those companies, as well as our next private deal in the legal marijuana space, click here now.

To a new way of life and a new generation of wealth...

Jeff Siegel Signature

Jeff Siegel

follow basic@JeffSiegel on Twitter

Jeff is the founder and managing editor of Green Chip Stocks, a private investment community that capitalizes on opportunities in alternative energy, organic food markets, legal cannabis, and socially-responsible investing. He has been a featured guest on Fox, CNBC, and Bloomberg Asia, and is the author of the best-selling book, Investing in Renewable Energy: Making Money on Green Chip Stocks. For more on Jeff, go to his editor''''s page.

Feedback
Did you like this article? Let us know!  
Related Articles
Martin Shkreli and the Case for Investing in Marijuana
Investing in California Marijuana
Marijuana Investments for March 2016
Browse Our Archives
How to Buy Great Companies
Investing in Smart Grid Stocks
Driving in a Bubble
Drones 2.0 The Next Frontier
A Natural Gas Trade
This email was sent to newsletter@newslettercollector.com. You can manage your subscription and get our privacy policy here.
Wealth Daily, Copyright © 2016, Angel Publishing, 111 Market Place #720, Baltimore, MD 21202. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Wealth Daily does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law.
It is not our intention to send email to anyone who doesn't want it. If you're not sure why you're getting this e-letter, or no longer wish to receive it, get more info here, including our privacy policy and information on how to manage your subscription.